# Patent

## Title
Carbazole derivatives acting on 5-HT7 receptor

## Abstract

The present invention provides a carbazole derivative represented by Formula 1:




wherein X is CH2 or C(O), Y is selected from NR1R2, piperidinyl groups in which two of the carbon atoms are substituted with R3 and R4, piperazinyl groups in which the nitrogen atom is substituted with R5, and morpholinyl groups, n is an integer from 2 to 5, R1 and R2, which may be identical or different, are each independently selected from C1-C6 alkyl, phenyl, and benzyl, with the proviso that R1 and R2 may be bonded together to form a ring, R3 and R4, which may be identical or different, are each independently selected from hydrogen, C1-C6 alkyl, phenyl, and benzyl, and R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl; or a pharmaceutically acceptable salt thereof.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority under 35 U.S.C. §119 to Korean Patent Application No. 10-2014-0048074 filed on Apr. 22, 2014 in the Korean Intellectual Property Office, the disclosure of which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to carbazole derivatives and pharmaceutically acceptable salts thereof that act on the 5-HT7 receptor, methods for preparing the compounds, and pharmaceutical compositions containing the compounds as active ingredients.
2. Description of the Related Art
The neurotransmitter serotonin acts on 14 different serotonin receptors distributed in various organs and is responsible for various physiological phenomena. Of these, the 5-HT7 subtype is the most recently cloned serotonin receptor and is known to be abundantly distributed, particularly in the hypothalamus, thalamus, hippocampus, and cortex. The 5-HT7 receptor is also found in peripheral tissues, such as spleen, stomach, intestine, and coronary artery, as well as in the brain tissues. Such expression patterns indicate that the 5-HT7 receptor is involved in various functions and pathologies. Particularly, the 5-HT7 receptor is known to perform important functions in thermoregulation, circadian rhythm, learning and memory, sleep, and hippocampal signal transduction (Lowenberg, T. N. et al., Neuron (1993) 11: 449-458). The 5-HT7 receptor is also known to be implicated in neurological diseases, such as depression, migraine, anxiety, and pain, particularly inflammatory pain and neuropathic pain (see a) Schoeffter, P. et al. Br J Pharmacol (1996) 117: 993-994; b) Terron, J. A., Eur. J. Pharmacol (2002) 439: 1-11).
Numerous efforts have been made so far to develop 5-HT7 receptor antagonists and agonists. However, only a few selective 5-HT7 receptor antagonists were reported. For example, International Patent Publication Nos. WO 97/48681, WO 97/29097, WO 97/49695, WO 00/56712, and WO 03/48118 disclose sulfonamide-based antagonists. Further, International Patent Publication Nos. WO 99/24022 and WO 00/000472 disclose tetrahydroisoquinoline derivatives acting on the 5-HT7 receptor.
Despite the research, a need still exists to find compounds that have selective pharmacological activities against the 5-HT7 receptor, achieving excellent pharmacological effects against 5-HT7 receptor-mediated diseases and conditions and good pharmaceutical properties in terms of administration, dispersion, uptake, distribution, metabolism, and excretion.
SUMMARY OF THE INVENTION
It is a first object of the present invention to provide carbazole derivatives and pharmaceutically acceptable salts thereof that act on the 5-HT7 receptor.
It is a second object of the present invention to provide methods for preparing the carbazole derivatives.
It is a third object of the present invention to provide pharmaceutical compositions which include the carbazole derivatives and the pharmaceutically acceptable salts thereof as active ingredients and are thus effective in treating or preventing central nervous system diseases, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, circadian rhythm dysregulation, sleep disturbance, and smooth muscle-related diseases.
One aspect of the present invention provides a carbazole derivative represented by Formula 1:




wherein X is CH2 or C(O), Y is selected from NR1R2, piperidinyl groups substituted with R3 and R4, piperazinyl groups in which the nitrogen atom is substituted with R5, and morpholinyl groups, n is an integer from 2 to 5, R1 and R2, which may be identical or different, are each independently selected from C1-C6 alkyl, phenyl, and benzyl, with the proviso that R1 and R2 may be bonded together to form a ring, R3 and R4, which may be identical or different, are each independently selected from hydrogen, C1-C6 alkyl, phenyl, and benzyl, and R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl, or a pharmaceutically acceptable salt thereof; and
a pharmaceutical composition including the carbazole derivative or pharmaceutically acceptable salt thereof as an active ingredient.
A further aspect of the present invention provides a method for preparing the carbazole derivative represented by Formula 1, including alkylating or acylating carbazole to prepare a carbazole intermediate and reacting the carbazole intermediate with a secondary amine compound.
Another aspect of the present invention provides a pharmaceutical composition for preventing and treating a central nervous system disease, including the carbazole derivative represented by Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient.
The central nervous system disease may be selected from the group consisting of depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, circadian rhythm dysregulation, sleep disturbance, smooth muscle-related diseases, and combinations thereof.
The carbazole derivative and the pharmaceutically acceptable salt thereof according to the present invention exhibit high binding affinities for and antagonistic activities against the 5-HT7 serotonin receptor. Therefore, the pharmaceutical composition of the present invention, which includes the carbazole derivative or pharmaceutically acceptable salt thereof as an active ingredient, is effective in treating and preventing central nervous system diseases where antagonistic activities against 5-HT7 are required, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, circadian rhythm dysregulation, sleep disturbance, and smooth muscle-related diseases.



BRIEF DESCRIPTION OF THE DRAWINGS
These and/or other aspects and advantages of the invention will become apparent and more readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings of which:
FIG. 1 shows the preventive effect of a compound prepared in Example 2.10 on migraine.



DETAILED DESCRIPTION OF THE INVENTION
The present invention will now be described in more detail.
In one aspect, the present invention provides a carbazole derivative represented by Formula 1:




wherein X is CH2 or C(O), Y is selected from NR1R2, piperidinyl groups in which two of the carbon atoms are substituted with R3 and R4, piperazinyl groups in which the nitrogen atom is substituted with R5, and morpholinyl groups, n is an integer from 2 to 5, R1 and R2, which may be identical or different, are each independently selected from C1-C6 alkyl, phenyl, and benzyl, with the proviso that R1 and R2 may be bonded together to form a ring, R3 and R4, which may be identical or different, are each independently selected from hydrogen, C1-C6 alkyl, phenyl, and benzyl, and R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl; or a pharmaceutically acceptable salt thereof.
When Y in Formula 1 is NR1R2, R1 and R2 may be bonded together to form a ring. In this case, Y may be, for example, a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, and azepanyl. The heterocyclic group may be substituted with C1-C5 alkyl.
In the present invention, Y in Formula 1 may be particularly selected from, but not limited to, methylbutylaminyl, methylbenzylaminyl, pyrrolidinyl, azepanyl, morpholinyl, 4-methylpiperidinyl, 3-methylpiperidinyl, 3,5-dimethylpiperidinyl, 4-phenylpiperidinyl, 4-benzylpiperidinyl, 4-methylpiperazinyl, 4-acetylpiperazinyl, 4-(2-methoxyphenyl)piperazinyl, 4-(2-hydroxyphenyl)piperazinyl, 4-benzylpiperazinyl, and 4-(benzoisoxazol-3-yl)piperazinyl.
In the present invention, the C1-C6 alkyl may be linear or branched alkyl. Specifically, the C1-C6 alkyl may be selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, hexyl, and isohexyl.
In the present invention, the C1-C4 alkylcarbonyl may be selected from acetyl, propionyl, and butanon-1-yl.
In the present invention, the phenyl substituted with C1-C4 alkyloxy may be selected from the group consisting of methoxyphenyl, ethoxyphenyl, propoxyphenyl, dimethoxyphenyl, diethoxyphenyl, and trimethoxyphenyl.
In the present invention, the pharmaceutically acceptable salt may be prepared using any suitable acid commonly used in the art. Specific examples of such acids include, but are not particularly limited to: non-toxic inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfonic acid, amidosulfuric acid, phosphoric acid, and nitric acid; and non-toxic organic acids, such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, tartaric acid, citric acid, para-toluenesulfonic acid, and methanesulfonic acid.
In the present invention, the carbazole derivative represented by Formula 1 may be selected from compounds represented by Formulae 2 to 5:




wherein X, n, R1, and R2 are as defined in Formula 1;




wherein X, n, R2, and R3 are as defined in Formula 1;




wherein X, n, and R5 are as defined in Formula 1; and




wherein X and n are as defined in Formula 1.
In Formula 2, the dashed line between R1 and R2 indicates that R1 and R2 may be optionally linked together to form a condensed ring.
In the present invention, the carbazole derivative represented by Formula 1 is particularly preferably selected from the following Compounds 1 to 60:
Compound 1: 6-(Butyl(methyl)amino)-1-(9H-carbazol-9-yl)hexan-1-one




Compound 2: 6-(Benzyl(methyl)amino)-1-(9H-carbazol-9-yl)hexan-1-one




Compound 3: 1-(9H-carbazol-9-yl)-6-(pyrrolidin-1-yl)hexan-1-one




Compound 4: 1-(9H-carbazol-9-yl)-6-(4-methylpiperidin-1-yl)hexan-1-one




Compound 5: 1-(9H-carbazol-9-yl)-6-(3-methylpiperidin-1-yl)hexan-1-one




Compound 6: 1-(9H-carbazol-9-yl)-6-(3,5-dimethylpiperidin-1-yl)hexan-1-one




Compound 7: 6-(Azepan-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one




Compound 8: 1-(9H-carbazol-9-yl)-6-morpholinohexan-1-one




Compound 9: 1-(9H-carbazol-9-yl)-6-(4-phenylpiperidin-1-yl)hexan-1-one




Compound 10: 6-(4-Benzylpiperidin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one




Compound 11: 6-(4-Acetylpiperazin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one




Compound 12: 1-(9H-carbazol-9-yl)-6-(4-methylpiperazin-1-yl)hexan-1-one




Compound 13: 6-(4-Benzylpiperazin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one




Compound 14: 6-(4-Benzo[d]isoxazol-3-yl)piperazin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one




Compound 15: 1-(9H-carbazol-9-yl)-6-(4-(2-hydroxyphenyl)piperazin-1-yl)hexan-1-one




Compound 16: 1-(9H-carbazol-9-yl)-6-(4-(2-methoxyphenyl)piperazin-1-yl)hexan-1-one




Compound 17: 5-(Butyl(methyl)amino)-1-(9H-carbazol-9-yl)pentan-1-one




Compound 18: 5-(Benzyl(methyl)amino)-1-(9H-carbazol-9-yl)pentan-1-one




Compound 19: 1-(9H-carbazol-9-yl)-5-(pyrrolidin-1-yl)pentan-1-one




Compound 20: 1-(9H-carbazol-9-yl)-5-(4-methylpiperidin-1-yl)pentan-1-one




Compound 21: 1-(9H-carbazol-9-yl)-5-(3-methylpiperidin-1-yl)pentan-1-one




Compound 22: 1-(9H-carbazol-9-yl)-5-(3,5-dimethylpiperidin-1-yl)pentan-1-one




Compound 23: 5-(Azepan-1-yl)-1-(9H-carbazol-9-yl)pentan-1-one




Compound 24: 1-(9H-carbazol-9-yl)-5-morpholinopentan-1-one




Compound 25: 1-(9H-carbazol-9-yl)-5-(4-phenylpiperidin-1-yl)pentan-1-one




Compound 26: 5-(4-Benzylpiperidin-1-yl)-1-(9H-carbazol-9-yl)pentan-1-one




Compound 27: 5-(4-Acetylpiperazin-1-yl)-1-(9H-carbazol-9-yl)pentan-1-one




Compound 28: 1-(9H-carbazol-9-yl)-5-(4-methylpiperazin-1-yl)pentan-1-one




Compound 29: 5-(4-Benzylpiperazinyl)-1-(9H-carbazol-9-yl)pentan-1-one




Compound 30: 1-(9H-carbazol-9-yl)-5-(4-(2-hydroxyphenyl)piperazin-1-yl)pentan-1-one




Compound 31: 1-(9H-carbazol-9-yl)-5-(4-(2-methoxyphenyl)piperazin-1-yl)pentan-1-one




Compound 32: 4-(4-Benzylpiperazin-1-yl)-1-(9H-carbazol-9-yl)butan-1-one




Compound 33: 1-(9H-carbazol-9-yl)-4-(4-(2-hydroxyphenyl)piperazin-1-yl)butan-1-one




Compound 34: 1-(9H-carbazol-9-yl)-4-(4-(2-methoxyphenyl)piperazin-1-yl)butan-1-one




Compound 35: N-butyl-6-(9H-carbazol-9-yl)-N-methylhexane-1-amine




Compound 36: N-benzyl-6-(9H-carbazol-9-yl)-N-methylhexane-1-amine




Compound 37: 9-(6-(Pyrrolidin-1-yl)hexyl)-9H-carbazole




Compound 38: 9-(6-(4-Methylpiperidin-1-yl)hexyl)-9H-carbazole




Compound 39: 9-(6-(3-Methylpiperidin-1-yl)hexyl)-9H-carbazole




Compound 40: 9-(6-(3,5-Dimethylpiperidin-1-yl)hexyl)-9H-carbazole




Compound 41: 9-(6-(Azepan-1-yl)hexyl)-9H-carbazole




Compound 42: 4-(6-(9H-carbazol-9-yl)hexyl)morpholine




Compound 43: 9-(6-(4-Phenylpiperidin-1-yl)hexyl)-9H-carbazole




Compound 44: 9-(6-(4-Benzylpiperidin-1-yl)hexyl)-9H-carbazole




Compound 45: 1-(4-(6-(9H-carbazol-9-yl)hexyl)piperazin-1-yl)ethanone




Compound 46: 9-(6-(4-Methylpiperazin-1-yl)hexyl)-9H-carbazole




Compound 47: 9-(6-(4-Benzylpiperazin-1-yl)hexyl)-9H-carbazole




Compound 48: 2-(4-(6-(9H-carbazol-9-yl)hexyl)piperazin-1-yl)phenol




Compound 49: 9-(6-(4-(2-Methoxyphenyl)piperazin-1-yl)hexyl)-9H-carbazole




Compound 50: 9-(5-(4-Phenylpiperidin-1-yl)pentyl)-9H-carbazole




Compound 51: 9-(5-(4-Benzylpiperazin-1-yl)pentyl)-9H-carbazole




Compound 52: 2-(4-(5-(9H-carbazol-9-yl)pentyl)piperazin-1-yl)phenol




Compound 53: 9-(5-(4-(2-Methoxyphenyl)piperazin-1-yl)pentyl)-9H-carbazole




Compound 54: 9-(4-(4-Phenylpiperidin-1-yl)butyl)-9H-carbazole




Compound 55: 2-(4-(4-(9H-carbazol-9-yl)butyl)piperazin-1-yl)phenol




Compound 56: 9-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-9H-carbazole




Compound 57: 9-(3-(4-Phenylpiperidin-1-yl)propyl)-9H-carbazole




Compound 58: 9-(3-(4-Benzylpiperazin-1-yl)propyl)-9H-carbazole




Compound 59: 2-(4-(3-(9H-carbazol-9-yl)propyl)piperazin-1-yl)phenol




and

Compound 60: 9-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propyl)-9H-carbazole




In a further aspect, the present invention provides a method for preparing a carbazole compound represented by Formula 1:




wherein X, Y, and n are as defined above, the method including reacting a compound represented by Formula 6:




wherein X and n are as defined above, with a compound represented by Formula 7:

Y—H  (7)

wherein Y is as defined above, in an organic solvent.
The organic solvent may be selected from the group consisting of acetonitrile, dichloromethane, dichloroethane, tetrahydrofuran, lower alcohol, N,N-dimethylformamide, dimethyl sulfoxide, ethyl acetate, dioxane, chloroform, benzene, and toluene.
The reaction may be carried out under reflux at 25 to 300° C. for 3 to 24 hours.
The reaction may be carried out in the presence of a base for improved reactivity. The base may be selected from K2CO3, triethylamine, and diisopropylethylamine.
In the present invention, the lower alcohol may be methanol, ethanol, propanol or butanol.
According to one embodiment of the present invention, the reaction mixture may be extracted with a suitable organic solvent known in the art. Specifically, the reaction mixture is diluted with an organic solvent selected from dichloromethane, diethyl ether, and ethyl acetate, a weakly acidic aqueous solution is added thereto, the organic layer is separated from the aqueous layer, the remaining water molecules are removed from the organic layer, followed by concentration and purification.
The purification may be performed by any suitable technique known in the art, preferably column chromatography on silica gel, to obtain the desired carbazole derivative represented by Formula 1.
The pharmaceutically acceptable salt of the carbazole derivative represented by Formula 1 may be prepared using a non-toxic inorganic or organic acid. Examples of suitable non-toxic inorganic acids include hydrochloric acid, hydrobromic acid, sulfonic acid, amidosulfuric acid, phosphoric acid, and nitric acid. Examples of suitable non-toxic organic acids include acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, tartaric acid, citric acid, para-toluenesulfonic acid, and methanesulfonic acid.
According to one embodiment of the present invention, the compound of Formula 6 may be prepared by reacting carbazole with a compound of Formula 8:




wherein X and n are as defined above, in an organic solvent.
The organic solvent may be selected from the group consisting of acetonitrile, dichloromethane, dichloroethane, tetrahydrofuran, lower alcohol, N,N-dimethylformamide, dimethyl sulfoxide, ethyl acetate, dioxane, chloroform, benzene, and toluene.
The reaction may be carried out under reflux at 25 to 200° C. for 3 to 24 hours. The desired compound may be obtained by any suitable purification technique known in the art. Preferably, the carbazole compound of Formula 6 is purified by column chromatography on silica gel.
According to one embodiment of the present invention, when X in Formula 8 is CH2, the reaction for the preparation of the compound of Formula 6 may be carried out in the presence of a base. The base may be selected from t-BuOK, triethylamine, and diisopropylethylamine. When X is C(O), the reaction for the preparation of the compound of Formula 6 is preferably carried out in the dark, where improved reactivity is ensured and side reactions are prevented.
In another aspect, the present invention provides a pharmaceutical composition for preventing and treating a central nervous system disease, including the carbazole compound represented by Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient.
The central nervous system disease may be selected from the group consisting of depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, circadian rhythm dysregulation, sleep disturbance, smooth muscle-related diseases, and combinations thereof.
The pharmaceutical composition of the present invention has a binding affinity for the 5-HT7 receptor and exhibits an inhibitory activity against the 5-HT7 receptor due to its selective antagonism against the 5-HT7 receptor.
According to one embodiment of the present invention, the carbazole compound or pharmaceutically acceptable salt thereof may be mixed with a carrier, excipient or diluent known in the art and the mixture may be formulated into a dosage form suitable for oral or parenteral administration by any suitable technique known in the art.
Examples of such carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil.
For formulation, the pharmaceutical composition may further include at least one additive selected from fillers, extenders, binders, wetting agents, disintegrants, and surfactants known in the art. A lubricating agent such as magnesium stearate or talc may be further added during formulation.
For oral administration, the pharmaceutical composition may be in the form of tablets, capsules, solutions, suspensions, and the like. For parenteral administration, the pharmaceutical composition may be in the form of preparations for intraperitoneal, subcutaneous, intramuscular, and transdermal injections.
According to one embodiment of the present invention, the pharmaceutical composition is a 5-HT7 serotonin receptor modulator. The pharmaceutical composition is administered in an amount such that the effective dose of the carbazole derivative of Formula 1 or pharmaceutically acceptable salt thereof ranges from 0.01 to 1000 mg/day for an adult. The daily dose may depend on the age, weight, sex, and general health of the patient, the mode of administration, and the severity of diseases to be treated. The daily dose may be administered in a single dose or in divided doses at regular time intervals according to the judgment of the physician or pharmacist.
Thus, the present invention provides the medical use of the carbazole compound represented by Formula 1 or pharmaceutically acceptable salt thereof or the pharmaceutical composition for the prevention and treatment of diseases.
Specifically, the present invention includes the medical use of the carbazole compound represented by Formula 1 or pharmaceutically acceptable salt thereof or the pharmaceutical composition, which acts as a 5-HT7 serotonin receptor modulator, for the prevention and treatment of neurological diseases, such as depression, migraine, anxiety, and pain, particularly inflammatory pain and neuropathic pain, body temperature dysregulation, circadian rhythm dysregulation, sleep disturbance, and smooth muscle-related diseases.
The present invention will be explained in more detail with reference to the following examples. However, it will be obvious to those skilled in the art that these examples are provided for illustrative purposes only and are not intended to limit the scope of the invention.
EXAMPLES
Example 1.1: 6-Bromo-1-(9H-carbazol-9-yl)hexan-1-one
Carbazole (2 g, 11.96 mmol) was dissolved in toluene (100 ml) in the reactor, which was covered with a foil to prevent light from entering. To the solution was added 6-bromohexanoyl chloride (5.1 g, 23.92 mmol). The mixture was heated to reflux at 115° C. for 18 h. After completion of the reaction, the reaction solution was concentrated under reduced pressure and diluted with CH2C12. The diluted solution was washed with 1 N HCl and H2O, dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduced pressure. The resulting concentrate was purified by silica gel column chromatography (hexane:EtOAc=20:1), giving 3.4 g (9.88 mmol, 83% yield) of the title compound.
1H NMR (400 MHz, CDCl3) δ 7.77 (dd, J=7.7 Hz, J=1.2 Hz, 1H), 7.64 (td, J=7.7 Hz, J=1.2 Hz, 1H), 7.58-7.42 (m, 7H)
Example 1.2: 5-Bromo-1-(9H-carbazol-9-yl)pentan-1-one
The title compound was prepared in the same manner as in Example 1.1, except that 5-bromopentanoyl chloride was used instead of 6-bromohexanoyl chloride.
Example 1.3: 4-Bromo-1-(9H-carbazol-9-yl)butan-1-one
The title compound was prepared in the same manner as in Example 1.1, except that 4-bromobutanoyl chloride was used instead of 6-bromohexanoyl chloride.
Example 1.4: 9-(6-Bromohexyl)-9H-carbazole
Carbazole (2 g, 11.96 mmol), 1,6-dibromohexane (2.8 ml, 17.94 mmol), and t-BuOK (1.3 g, 11.96 mmol) were dissolved in THF (15 ml) in a reactor. The solution was stirred under heating at 40° C. for 10 h. After completion of the reaction, the reaction solution was concentrated under reduced pressure and diluted with CH2C12. The diluted solution was washed with H2O, dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography (hexane:MC=8:1), giving 2.1 g (6.36 mmol, 53% yield) of the title compound.
1H NMR (400 MHz, CDCl3) δ 8.03-8.01 (m, 2H), 7.39-7.35 (m, 2H), 7.25 (d, J=8.2 Hz, 2H), 7.15 (td, J=7.4 Hz, J=0.8 Hz, 2H), 4.07 (t, J=7.1 Hz, 2H), 3.17 (t, J=6.7 Hz, 2H), 1.72-1.57 (m, 4H), 1.30-1.14 (m, 4H)
Example 1.5: 9-(5-Bromopentyl)-9H-carbazole
The title compound was prepared in the same manner as in Example 1.4, except that 1,5-dibromopentane was used instead of 1,6-dibromohexane.
Example 1.6: 9-(4-Bromobutyl)-9H-carbazole
The title compound was prepared in the same manner as in Example 1.4, except that 1,4-dibromobutane was used instead of 1,6-dibromohexane.
Example 1.7: 9-(3-Bromopropyl)-9H-carbazole
The title compound was prepared in the same manner as in Example 1.4, except that 1,3-dibromopropane was used instead of 1,6-dibromohexane.
Example 2
Example 2.1: 6-(Butyl(methyl)amino)-1-(9H-carbazol-9-yl)hexan-1-one hydrochloride
The compound of Example 1.1 (100 mg, 0.29 mmol) and N-methylbutylamine (0.02 ml, 0.35 mmol) were dissolved in acetonitrile (10 ml) in a reactor. The solution was heated to reflux at 85° C. for 21 h. After completion of the reaction, the reaction mixture was diluted with CH2C12, and 0.5 N HCl and H2O were then added thereto. The aqueous layer was extracted with CH2C12. The obtained organic layer was dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography (MC:MeOH=20:1). The crude product was added dropwise to a solution of 0.5 N hydrochloric acid (0.30 ml, 0.34 mmol) in dimethyl ether to obtain a solid precipitate. Filtration of the precipitate gave 64.4 mg (0.17 mmol, 57% yield) of the title compound.
1H NMR (400 MHz, CDCl3) δ 11.57 (brs, 0.8H), 8.21 (d, J=8.4 Hz, 2H), 7.99 (dd, J=5.7 Hz, J=0.9 Hz, 2H), 7.48 (td, J=7.8 Hz, J=1.2 Hz, 2H), 7.38 (t, J=7.2 Hz, 2H), 3.19 (t, J=6.7 Hz, 2H), 3.11-2.90 (m, 4H), 2.76 (d, J=4.6 Hz, 3H), 2.04-1.77 (m, 6H), 1.63-1.58 (m, 2H), 1.45-1.36 (m, 2H), 0.97 (t, J=7.3 Hz, 3H)
Example 2.2: 6-(Benzyl)methyl)amino)-1-(9H-carbazol-9-yl)hexan-1-one hydrochloride
70.0 mg (0.17 mmol, 57% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and N-benzylmethylamine (0.04 ml, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 12.08 (brs, 0.8H), 8.22 (d, J=8.4 Hz, 2H), 8.00 (dd, J=5.7 Hz, J=0.9 Hz, 2H), 7.61-7.59 (m, 2H), 7.51-7.38 (m, 7H), 4.18 (brd, J=12.6 Hz, 2H), 3.18 (t, J=6.7 Hz, 2H), 3.12 (brs, 1H), 2.89 (brs, 1H), 2.69 (s, 3H), 2.12 (brs, 1H), 1.97 (quint, J=7.1 Hz, 3H), 1.58 (brs, 2H)
Example 2.3: 1-(9H-carbazol-9-yl)-6-(pyrrolidin-1-yl)hexan-1-one hydrochloride
98.0 mg (0.26 mmol, 91% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and pyrrolidine (0.03 ml, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (300 MHz, CDCl3) δ 11.85 (brs, 0.8H), 8.22 (d, J=8.2 Hz, 2H), 8.00 (d, J=7.2 Hz, 2H), 7.49 (t, J=7.4 Hz, 2H), 7.39 (t, J=7.4 Hz, 2H), 3.82 (brs, 2H), 3.19 (t, J=6.3 Hz, 2H), 3.09 (brs, 2H), 2.79 (brs, 2H), 2.26 (brs, 2H), 2.06-1.99 (m, 6H), 1.64 (s, 2H)
Example 2.4: 1-(9H-carbazol-9-yl)-6-(4-methylpiperidin-1-yl)hexan-1-one
The compound of Example 1.1 (100 mg, 0.29 mmol) and 4-methylpiperidine (0.04 ml, 0.35 mmol) were dissolved in acetonitrile (10 ml) in a reactor. The solution was heated to reflux at 85° C. for 21 h. After completion of the reaction, the reaction mixture was diluted with CH2C12, and 0.5 N HCl and H2O were then added thereto. The aqueous layer was extracted with CH2C12. The obtained organic layer was dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography (hexane:EtOAc=4:1), giving 51 mg (0.14 mmol, 48% yield) of the final title compound.
1H NMR (300 MHz, CDCl3) δ 8.22 (d, J=8.3 Hz, 2H), 8.02-7.99 (m, 2H), 7.51-7.45 (m, 2H), 7.38 (td, J=7.5 Hz, J=0.9 Hz, 2H), 3.16 (t, J=7.4 Hz, 2H), 2.91 (brd, J=11.7 Hz, 2H), 2.36 (t, J=7.6 Hz, 2H), 2.04-1.83 (m, 4H), 1.67-1.47 (m, 6H), 1.38-1.19 (m, 3H), 0.92 (d, J=6.0 Hz, 3H)
Example 2.5: 1-(9H-carbazol-9-yl)-6-(3-methylpiperidin-1-yl)hexan-1-one hydrochloride
63.6 mg (0.16 mmol, 55% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and 3-methylpiperidine (0.04 ml, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 11.22 (brs, 0.8H), 8.23 (d, J=8.4 Hz, 2H), 8.01 (dd, J=5.7 Hz, J=0.9 Hz, 2H), 7.52-7.47 (m, 2H), 7.39 (t, J=7.3 Hz, 2H), 3.57 (brd, J=10.2 Hz, 1H), 3.49-3.43 (m, 1H), 3.20 (t, J=6.7 Hz, 2H), 2.98-2.97 (m, 2H), 2.54-2.37 (m, 3H), 2.21 (q, J=10.9 Hz, 1H), 2.08-1.85 (m, 7H), 1.59 (s, 1H), 1.14-1.04 (m, 1H), 0.96 (d, J=6.6 Hz, 3H)
Example 2.6: 1-(9H-carbazol-9-yl)-6-(3,5-dimethylpiperidin-1-yl)hexan-1-one hydrochloride
82.5 mg (0.20 mmol, 69% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and 3,5-dimethylpiperidine (0.05 ml, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 11.64 (brs, 0.8H) 8.22 (d, J=8.3 Hz, 2H), 8.00 (d, J=7.6 Hz, 2H), 7.49 (t, J=7.4 Hz, 2H), 7.39 (t, J=7.4 Hz, 2H), 3.40 (brd, J=9.2 Hz, 2H), 3.19 (t, J=6.2 Hz, 2H), 2.96 (brs, 2H), 2.52 (brs, 2H), 2.16-1.90 (m, 7H), 1.58 (brs, 3H), 0.95 (d, J=6.3 Hz, 6H);
Example 2.7: 6-(Azepan-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one hydrochloride
95.7 mg (0.24 mmol, 83% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and hexamethyleneimine (0.04 ml, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (300 MHz, CDCl3) δ 11.53 (brs, 0.8H), 8.22 (d, J=8.3 Hz, 2H), 8.00 (d, J=7.6 Hz, 2H), 7.49 (t, J=7.8 Hz, 2H), 7.39 (t, J=7.4 Hz, 2H), 3.56-3.54 (m, 2H), 3.19 (t, J=6.7 Hz, 2H), 3.03-2.88 (m, 4H), 2.22-2.15 (m, 2H), 2.04-1.94 (m, 4H), 1.87-1.81 (m, 4H), 1.61 (s, 4H)
Example 2.8: 1-(9H-carbazol-9-yl)-6-morpholinohexan-1-one hydrochloride
31.6 mg (0.08 mmol, 28% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and morpholine (0.03 ml, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 12.75 (brs, 0.8H), 8.22 (brd, J=6.7 Hz, 2H), 8.00 (d, J=7.6 Hz, 2H), 7.49 (brs, 2H), 7.39 (t, J=7.2 Hz, 2H), 4.36 (brs, 2H), 3.99 (brs, 2H), 3.49-3.45 (m, 2H), 3.20 (brs, 2H), 3.04 (brs, 2H), 2.88 (brs, 2H), 2.05 (brd, J=30.7 Hz, 4H), 1.60 (s, 2H)
Example 2.9: 1-(9H-carbazol-9-yl)-6-(4-phenylpiperidin-1-yl)hexan-1-one hydrochloride
45.6 mg (0.10 mmol, 34% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and 4-phenylpiperidine (56 mg, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 11.95 (brs, 0.8H), 8.23 (d, J=8.4 Hz, 2H), 8.01 (dd, J=5.7 Hz, J=0.8 Hz, 2H), 7.52-7.48 (m, 2H), 7.40 (t, J=7.5 Hz, 2H), 7.34-7.23 (m, 5H), 3.70 (brd, J=10.2 Hz, 2H), 3.21 (t, J=6.7 Hz, 2H), 3.04 (brs, 2H), 2.80-2.65 (m, 4H), 2.11 (brs, 3H), 2.02 (brd, J=11.0 Hz, 3H), 1.63-1.58 (m, 3H)
Example 2.10: 6-(4-Benzylpiperidin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one hydrochloride
88.4 mg (0.19 mmol, 64% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and 4-benzylpiperidine (0.06 ml, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 11.51 (brs, 0.8H), 8.22 (brs, 2H), 7.99 (brd, J=6.6 Hz, 2H), 7.49 (brs, 2H), 7.38 (brs, 2H), 7.29 (brs, 2H), 7.22 (brs, 1H), 7.14 (brs, 2H), 3.66 (brs, 2H), 3.19 (brs, 2H), 3.03 (brs, 2H), 2.64 (s, 4H), 2.10 (brd, J=59.6 Hz, 6H), 1.85 (brs, 3H), 1.71 (s, 2H)
Example 2.11: 6-(4-Acetylpiperazin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one hydrochloride
55.4 mg (0.13 mmol, 45% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and acetylpiperazine (45 mg, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, MeOD) δ 8.24 (brs, 2H), 8.05 (brs, 2H), 7.47 (brs, 2H), 7.38 (brd, J=3.3 Hz, 2H), 4.64 (brd, J=12.9 Hz, 1H), 4.12 (brs, 1H), 3.59 (brs, 4H), 3.24-2.99 (m, 4H), 2.15 (s, 3H), 1.92 (brd, J=32.3 Hz, 5H), 1.59 (brs, 3H)
Example 2.12: 1-(9H-carbazol-9-yl)-6-(4-methylpiperazin-1-yl)hexan-1-one hydrochloride
83.8 mg (0.21 mmol, 72% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and methylpiperazine (0.03 ml, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, MeOD) δ 8.26 (d, J=8.4 Hz, 2H), 8.07 (d, J=7.6 Hz, 2H), 7.51-7.47 (m, 2H), 7.39 (t, J=7.4 Hz, 2H), 3.48-3.24 (m, 10H), 2.99 (brs, 2H), 2.78 (s, 3H), 1.96 (quint, J=7.3 Hz, 2H), 1.79 (brs, 2H), 1.58 (quint, J=7.5 Hz, 2H)
Example 2.13: 6-(4-Benzylpiperazin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one hydrochloride
135.0 mg (0.28 mmol, 98% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and benzylpiperazine (0.06 ml, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, DMSO) δ 11.48 (brs, 0.8H), 8.27 (d, J=8.4 Hz, 2H), 8.19 (dd, J=5.7 Hz, J=0.7 Hz, 2H), 7.60 (brs, 2H), 7.54-7.49 (m, 2H), 7.45-7.40 (m, 5H), 4.32 (brs, 2H), 3.66 (brs, 2H), 3.42 (s, 4H), 3.27 (t, J=7.0 Hz, 4H), 3.11 (brs, 2H), 1.83-1.77 (m, 4H), 1.49-1.47 (m, 2H)
Example 2.14: 6-(4-Benzo[d]isoxazol-3-yl)piperazin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one hydrochloride
6.3 mg (0.01 mmol, 4% yield) of the title compound was prepared using the compound of Example 1.1 (100 mg, 0.29 mmol) and 3-(1-piperazinyl)-1,2-benzisoxazole (71 mg, 0.35 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 13.21 (brs, 0.8H), 8.20 (brd, J=6.4 Hz, 2H), 7.99 (d, J=7.5 Hz, 2H), 7.61 (brs, 2H), 7.55-7.48 (m, 4H), 7.38 (t, J=7.1 Hz, 2H), 4.15 (brs, 4H), 3.56 (brs, 2H), 3.19 (brs, 2H), 3.05 (brs, 5H), 2.08-1.99 (m, 5H)
Example 2.15: 1-(9H-carbazol-9-yl)-6-(4-(2-hydroxyphenyl)piperazin-1-yl)hexan-1-one
195 mg (0.44 mmol, 76% yield) of the title compound was prepared using 1-(2-hydroxyphenyl)piperazine (124 mg, 0.70 mmol), the compound of Example 1.1 (200 mg, 0.58 mmol), and K2CO3 (80 mg, 0.58 mmol) in accordance with the procedure of Example 2.4.
1H NMR (300 MHz, CDCl3) δ 8.24 (d, J=9.0 Hz, 2H), 8.02 (dd, J=7.6, 0.7 Hz, 2H), 7.49 (td, J=7.8, 1.4 Hz, 2H), 7.40 (td, J=7.4, 0.8 Hz, 2H), 7.17 (dd, J=7.8, 1.2 Hz, 1H), 7.10-7.05 (m, 1H), 6.95 (dd, J=8.1, 1.5 Hz, 1H), 6.88-6.83 (m, 1H), 3.19 (t, J=7.4 Hz, 2H), 2.91 (brt, J=4.5 Hz, 4H), 2.63 (brs, 4H), 2.47 (t, J=7.2 Hz, 2H), 2.05-1.94 (m, 2H), 1.66-1.53 (m, 4H)
Example 2.16: 1-(9H-carbazol-9-yl)-6-(4-(2-methoxyphenyl)piperazin-1-yl)hexan-1-one
21 mg (0.046 mmol, 77% yield) of the title compound was prepared using 1-(2-methoxyphenyl)piperazine (13.4 mg, 0.07 mmol), the compound of Example 1.1 (20 mg, 0.06 mmol), and K2CO3 (8 mg, 0.06 mmol) in accordance with the procedure of Example 2.4.
1H NMR (300 MHz, CDCl3) δ 8.22 (d, J=8.4 Hz, 2H), 7.99 (dt, J=7.6, 0.7 Hz, 2H), 7.50-7.45 (m, 2H), 7.38 (td, J=7.4, 1.0 Hz, 2H), 7.02-6.92 (m, 4H), 3.86 (s, 3H), 3.17-3.12 (m, 6H), 2.66 (brs, 4H), 2.46 (t, J=7.5 Hz, 2H), 2.02-1.92 (m, 2H), 1.68-1.51 (m, 4H)
Example 2.17: 5-(Butyl(methyl)amino)-1-(9H-carbazol-9-yl)pentan-1-one hydrochloride
82.0 mg (0.22 mmol, 73% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and N-methylbutylamine (0.04 ml, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 11.41 (brs, 0.8H), 8.19 (d, J=8.3 Hz, 2H), 7.99 (d, J=7.5 Hz, 2H), 7.47 (t, J=7.5 Hz, 2H), 7.38 (t, J=7.5 Hz, 2H), 3.25 (t, J=6.0 Hz, 2H), 3.17-3.06 (m, 5H), 2.77 (s, 3H), 2.12 (brs, 2H), 2.02-2.00 (m, 2H), 1.90 (brs, 1H), 1.80 (brs, 1H), 1.40 (brd, J=6.7 Hz, 2H), 0.97 (t, J=7.3 Hz, 3H)
Example 2.18: 5-(Benzyl(methyl)amino)-1-(9H-carbazol-9-yl)pentan-1-one hydrochloride
90.7 mg (0.22 mmol, 74% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and N-benzylmethylamine (0.05 ml, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 12.72 (brs, 0.8H), 8.20 (d, J=8.2 Hz, 2H), 8.01 (dd, J=5.7 Hz, J=0.8 Hz, 2H), 7.62 (brd, J=3.4 Hz, 2H), 7.51-7.38 (m, 7H), 4.20 (q, J=14.0 Hz, 2H), 3.23-3.17 (m, 3H), 2.93 (brs, 1H), 2.72 (s, 3H), 2.18 (brd, J=33.3 Hz, 2H), 1.98 (brs, 2H)
Example 2.19: 1-(9H-carbazol-9-yl)-5-(pyrrolidin-1-yl)pentan-1-one hydrochloride
38.7 mg (0.11 mmol, 36% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and pyrrolidine (0.03 ml, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 11.66 (brs, 0.8H), 8.20 (d, J=8.3 Hz, 2H), 8.00 (d, J=7.2 Hz, 2H), 7.51-7.46 (m, 2H), 7.39 (t, J=7.3 Hz, 2H), 3.86-3.84 (m, 2H), 3.25 (t, J=6.7 Hz, 2H), 3.19-3.13 (m, 2H), 2.86-2.78 (m, 2H), 2.28-1.97 (m, 8H)
Example 2.20: 1-(9H-carbazol-9-yl)-5-(4-methylpiperidin-1-yl)pentan-1-one hydrochloride
44.2 mg (0.11 mmol, 38% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and 4-methylpiperidine (0.04 ml, 0.30 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 11.89 (brs, 0.8H), 8.20 (d, J=8.4 Hz, 2H), 7.99 (dd, J=5.7 Hz, J=0.9 Hz, 2H), 7.48 (td, J=7.8 Hz, J=1.2 Hz, 2H), 7.41-7.37 (m, 2H), 3.59 (brd, J=11.4 Hz, 2H), 3.25 (t, J=6.7 Hz, 2H), 3.02 (quint, J=5.3 Hz, 2H), 2.63 (q, J=10.8 Hz, 2H), 2.18-2.13 (m, 2H), 2.09-1.94 (m, 5H), 1.81 (brd, J=14.0 Hz, 2H), 1.07-1.03 (m, 3H)
Example 2.21: 1-(9H-carbazol-9-yl)-5-(3-methylpiperidin-1-yl)pentan-1-one hydrochloride
59.5 mg (0.15 mmol, 51% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and 3-methylpiperidine (0.04 ml, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 11.26 (brs, 0.8H) 8.20 (d, J=8.4 Hz, 2H), 7.98 (d, J=7.1 Hz, 2H), 7.50-7.45 (m, 2H), 7.38 (t, J=7.3 Hz, 2H), 3.58 (brd, J=10.4 Hz, 1H), 3.48-3.44 (m, 1H), 3.24 (t, J=6.7 Hz, 2H), 3.05 (brt, J=7.6 Hz, 2H), 2.58-2.14 (m, 6H), 2.00-1.85 (m, 5H), 0.95 (m, J=6.2 Hz, 3H)
Example 2.22: 1-(9H-carbazol-9-yl)-5-(3,5-dimethylpiperidin-1-yl)pentan-1-one hydrochloride
60.6 mg (0.15 mmol, 50% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and 3,5-dimethylpiperidine (0.05 ml, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 12.16 (brs, 0.8H), 8.19 (d, J=8.3 Hz, 2H), 7.99 (d, J=7.3 Hz, 2H), 7.49-7.45 (m, 2H), 7.38 (t, J=7.3 Hz, 2H), 3.41 (brd, J=11.0 Hz, 2H), 3.24 (t, J=6.7 Hz, 2H), 3.01 (brt, J=7.9 Hz, 2H), 2.47 (brs, 2H), 2.16-2.09 (m, 4H), 1.97 (quint, J=7.2 Hz, 2H), 1.89 (brd, J=13.2 Hz, 2H), 0.94 (d, J=6.6 Hz, 6H)
Example 2.23: 5-(Azepan-1-yl)-1-(9H-carbazol-9-yl)pentan-1-one hydrochloride
37.0 mg (0.10 mmol, 32% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and hexamethyleneimine (0.04 ml, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 11.39 (brs, 0.8H), 8.19 (d, J=8.3 Hz, 2H), 7.98 (dd, J=5.7 Hz, J=0.9 Hz, 2H), 7.47 (t, J=7.3 Hz, 2H), 7.38 (t, J=7.4 Hz, 2H), 3.58 (brs, 2H), 3.24 (t, J=6.0 Hz, 2H), 3.09 (brs, 2H), 2.95 (brs, 2H), 2.18 (s, 4H), 1.98-1.97 (m, 2H), 1.86-1.83 (m, 4H), 1.63 (s, 2H)
Example 2.24: 1-(9H-carbazol-9-yl)-5-morpholinopentan-1-one hydrochloride
80.7 mg (0.22 mmol, 71% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and morpholine (0.03 ml, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 12.94 (brs, 0.8H), 8.18 (d, J=8.2 Hz, 2H), 7.98 (d, J=7.3 Hz, 2H), 7.47 (t, J=7.5 Hz, 2H), 7.38 (t, J=7.4 Hz, 2H), 4.32 (t, J=12.0 Hz, 2H). 3.97 (d, J=11.6 Hz, 2H), 3.48-3.43 (m, 2H), 3.25 (s, 2H), 3.07 (s, 2H), 2.88 (s, 2H), 2.17 (s, 2H), 2.00 (s, 2H)
Example 2.25: 1-(9H-carbazol-9-yl)-5-(4-phenylpiperidin-1-yl)pentan-1-one hydrochloride
109.2 mg (0.24 mmol, 81% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and 4-phenylpiperidine (73 mg, 0.45 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 11.67 (brs, 0.8H), 8.21 (d, J=8.4 Hz, 2H), 7.99 (dd, J=5.8 Hz, J=0.8 Hz, 2H), 7.50-7.46 (m, 2H), 7.38 (td, J=7.5 Hz, J=0.7 Hz, 2H), 7.34-7.19 (m, 5H), 3.73 (brd, =10.4 Hz, 2H), 3.27 (t, J=6.7 Hz, 2H), 3.12-3.07 (m, 2H), 2.86-2.64 (m, 5H), 2.27-2.19 (m, 2H), 2.04-1.97 (m, 4H)
Example 2.26: 5-(4-Benzylpiperidin-1-yl)-1-(9H-carbazol-9-yl)pentan-1-one hydrochloride
113.5 mg (0.25 mmol, 81% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and 4-benzylpiperidine (0.06 ml, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 12.15 (brs, 0.8H), 8.18 (d, J=8.1 Hz, 2H), 7.98 (d, J=7.6 Hz, 2H), 7.46 (t, J=7.6 Hz, 2H), 7.37 (t, J=7.4 Hz, 2H), 7.29-7.17 (m, 3H), 7.11 (d, J=7.2 Hz, 2H), 3.57 (brd, J=9.8 Hz, 2H), 3.23 (s, 2H), 2.99 (s, 2H), 2.66-2.55 (m, 4H), 2.15-2.05 (m, 4H), 1.96 (s, 2H), 1.80 (d, J=13.5 Hz, 2H), 1.70 (brs, 1H)
Example 1.27: 5-(4-Acetylpiperazin-1-yl)-1-(9H-carbazol-9-yl)pentan-1-one hydrochloride
117.4 mg (0.28 mmol, 94% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and acetylpiperazine (47 mg, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, DMSO) δ 9.52 (brs, 0.8H), 8.29 (d, J=8.4 Hz, 2H), 8.21 (dd, J=5.8 Hz, J=0.8 Hz, 2H), 7.55-7.51 (m, 2H), 7.45-7.41 (m, 2H), 4.42 (brd, J=9.2 Hz, 1H), 4.01 (brd, J=14.4 Hz, 1H), 3.50 (brd, J=8.0 Hz, 2H), 3.41-3.32 (m, 2H), 3.20 (s, 2H), 3.04 (brd, J=10.0 Hz, 2H), 2.91 (brd, J=8.4 Hz, 2H), 2.03 (s, 3H), 1.83 (s, 4H)
Example 2.28: 1-(9H-carbazol-9-yl)-5-(4-methylpiperazin-1-yl)pentan-1-one hydrochloride
91.0 mg (0.24 mmol, 78% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and methylpiperazine (0.04 ml, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, DMSO) δ 11.61 (brs, 0.8H), 8.29 (d, J=8.4 Hz, 2H), 8.20 (dd, J=5.8 Hz, J=0.8 Hz, 2H), 7.55-7.50 (m, 2H), 7.44-7.40 (m, 2H), 3.32 (s, 9H), 3.16 (s, 3H), 2.72 (brs, 3H), 1.83 (s, 4H)
Example 2.29: 5-(4-Benzylpiperazinyl)-1-(9H-carbazol-9-yl)pentan-1-one hydrochloride
28.3 mg (0.06 mmol, 20% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and benzylpiperazine (0.06 ml, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, MeOD) δ 8.30 (d, J=8.4 Hz, 2H), 8.09 (d, J=7.6 Hz, 2H), 7.56 (brd, J=3.1 Hz, 2H), 7.52-7.48 (m, 5H), 7.43-7.39 (m, 2H), 4.34 (s, 2H), 3.82-3.21 (m, 12H), 2.00 (t, J=3.1 Hz, 4H)
Example 2.30: 1-(9H-carbazol-9-yl)-5-(4-(2-hydroxyphenyl)piperazin-1-yl)pentan-1-one hydrochloride
65.8 mg (0.14 mmol, 23% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and 1-(2-hydroxyphenyl)piperazine (162 mg, 0.91 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 10.22 (brs, 0.8H), 8.31 (d, J=8.4 Hz, 2H), 8.20 (dd, J=5.7 Hz, J=0.8 Hz, 2H), 7.53 (td, J=7.8 Hz, J=1.2 Hz, 2H), 7.43 (t, J=7.2 Hz, 2H), 6.90-6.81 (m, 3H), 6.75 (td, J=7.4 Hz, J=1.6 Hz, 1H), 3.47 (brd, J=12.8 Hz, 3H), 3.39-3.33 (m, 4H), 3.22-3.15 (m, 4H), 3.00 (t, J=11.5 Hz, 2H), 1.89-1.85 (m, 4H)
Example 2.31: 1-(9H-carbazol-9-yl)-5-(4-(2-methoxyphenyl)piperazin-1-yl)pentan-1-one hydrochloride
43.1 mg (0.09 mmol, 30% yield) of the title compound was prepared using the compound of Example 1.2 (100 mg, 0.30 mmol) and 1-(2-methoxyphenyl)piperazine (0.06 ml, 0.36 mmol) in accordance with the procedure of Example 2.1.
1H NMR (300 MHz, DMSO) δ 10.62 (brs, 0.8H), 8.32 (d, J=8.3 Hz, 2H), 8.22 (d, J=7.5 Hz, 2H), 7.56-7.51 (m, 2H), 7.43 (t, J=7.4 Hz, 2H), 7.05-6.87 (m, 4H), 3.79 (s, 3H), 3.53 (q, J=10.4 Hz, 4H), 3.35 (t, J=6.3 Hz, 2H), 3.23-3.02 (m, 6H), 1.91-1.85 (m, 4H)
Example 2.32: 4-(4-Benzylpiperazin-1-yl)-1-(9H-carbazol-9-yl)butan-1-one hydrochloride
27.7 mg (0.06 mmol, 17% yield) of the title compound was prepared using the compound of Example 1.3 (100 mg, 0.37 mmol) and benzylpiperazine (0.08 ml, 0.44 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 11.47 (brs, 0.8H), 8.33 (d, J=8.4 Hz, 2H), 8.20 (d, J=7.0 Hz, 2H), 7.59 (s, 3H), 7.54-7.49 (m, 2H), 7.44-7.41 (m, 4H), 4.30 (brs, 4H), 3.73-3.08 (m, 6H), 2.42 (t, J=7.3 Hz, 2H), 2.21-2.20 (m, 2H), 1.95-1.89 (m, 2H)
Example 2.33: 1-(9H-carbazol-9-yl)-4-(4-(2-hydroxyphenyl)piperazin-1-yl)butan-1-one
148.1 mg (0.36 mmol, 49% yield) of the title compound was prepared using the compound of Example 1.3 (200 mg, 0.74 mmol) and 1-(2-hydroxyphenyl)piperazine (197 mg, 1.10 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 8.27 (d, J=8.4 Hz, 2H), 8.03-8.01 (m, 2H), 7.52-7.47 (m, 2H), 7.40 (td, J=7.5 Hz, J=0.8 Hz, 2H), 7.08-7.03 (m, 2H), 6.93 (dd, J=6.0 Hz, J=1.2 Hz, 1H), 6.85-6.81 (m, 1H), 3.25 (t, J=7.0 Hz, 2H), 2.81 (t, J=4.7 Hz, 4H), 2.61 (t, J=7.0 Hz, 6H), 2.17 (quint, J=7.0 Hz, 2H)
Example 2.34: 1-(9H-carbazol-9-yl)-4-(4-(2-methoxyphenyl)piperazin-1-yl)butan-1-one
78 mg (0.18 mmol, 50% yield) of the title compound was prepared using the compound of Example 1.3 (100 mg, 0.37 mmol) and 1-(2-hydroxyphenyl)piperazine (197 mg, 1.10 mmol) in accordance with the procedure of Example 2.1.
1H NMR (400 MHz, CDCl3) δ 8.25 (d, J=8.4 Hz, 2H), 7.98 (d, J=7.6 Hz, 2H), 7.48-7.44 (m, 2H), 7.36 (t, J=7.4 Hz, 2H), 7.00-6.94 (m, 1H), 6.92-6.87 (m, 2H), 6.84 (d, J=7.9 Hz, 1H), 3.21 (t, J=7.1 Hz, 2H), 3.06 (s, 4H), 2.69 (s, 4H), 2.60 (t, J=7.0 Hz, 2H), 2.16 (quint, J=7.1 Hz, 2H)
Example 2.35: N-Butyl-6-(9H-carbazol-9-yl)-N-methylhexane-1-amine
The compound of Example 1.4 (100 mg, 0.30 mmol) and N-methylbutylamine (0.04 ml, 0.36 mmol) were dissolved in acetonitrile (10 ml) in a reactor. The solution was heated to reflux at 40° C. until the next day. After completion of the reaction, the reaction mixture was diluted with CH2C12, and H2O were then added thereto. The aqueous layer was extracted with CH2C12. The obtained organic layer was dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography (MC:MeOH=20:1), giving 68 mg (0.20 mmol, 67% yield) of the final title compound.
1H NMR (400 MHz, CDCl3) δ 8.06 (d, J=7.7 Hz, 2H), 7.45-7.40 (m, 2H), 7.36 (d, J=8.2 Hz, 2H), 7.22-7.18 (m, 2H), 4.25 (t, J=6.9 Hz, 2H), 2.82-2.71 (m, 4H), 2.54 (s, 3H), 1.83 (quint, J=7.2 Hz, 2H), 1.71-1.61 (m, 4H), 1.35-1.20 (m, 6H), 0.90 (t, J=7.4 Hz, 3H)
Example 2.36: N-Benzyl-6-(9H-carbazol-9-yl)-N-methylhexane-1-amine
111.0 mg (0.30 mmol, 99% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and N-benzylmethylamine (0.05 ml, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.06 (d, J=7.6 Hz, 2H), 7.44-7.39 (m, 2H), 7.34 (d, J=8.2 Hz, 2H), 7.29-7.24 (m, 4H), 7.23-7.17 (m, 3H), 4.21 (t, J=7.2 Hz, 2H), 3.40 (s, 2H), 2.26 (t, J=7.3 Hz, 2H), 2.11 (s, 3H), 1.80 (quint, J=7.2 Hz, 2H), 1.42 (quint, J=7.1 Hz, 2H), 1.36-1.24 (m, 4H)
Example 2.37: 9-(6-(Pyrrolidin-1-yl)hexyl)-9H-carbazole
61.4 mg (0.19 mmol, 63% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and pyrrolidine (0.03 ml, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.08 (d, J=7.7 Hz, 2H), 7.47-7.43 (m, 2H), 7.38 (d, J=8.2 Hz, 2H), 7.23-7.19 (m, 2H), 4.28 (t, J=6.8 Hz, 2H), 3.07 (brs, 3H), 2.78-2.74 (m, 2H), 2.04-2.02 (m, 4H), 1.84 (quint, J=7.2 Hz, 2H), 1.75-1.67 (m, 2H), 1.36-1.22 (m, 5H)
Example 2.38: 9-(6-(4-Methylpiperidin-1-yl)hexyl)-9H-carbazole
103 mg (0.30 mmol, 98% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and 4-methylpiperidine (0.04 ml, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.08 (d, J=7.7 Hz, 2H), 7.45-7.41 (m, 2H), 7.37 (d, J=8.1 Hz, 2H), 7.22-7.18 (m, 2H), 4.26 (t, J=7.2 Hz, 2H), 2.83 (brd, J=11.6 Hz, 2H), 2.22 (t, J=7.7 Hz, 2H), 1.88-1.80 (m, 4H), 1.58 (brd, J=12.6 Hz, 2H), 1.48-1.17 (m, 9H), 0.89 (d, J=6.1 Hz, 3H)
Example 2.39: 9-(6-(3-Methylpiperidin-1-yl)hexyl)-9H-carbazole
98.0 mg (0.28 mmol, 93% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and 3-methylpiperidine (0.04 ml, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.08 (d, J=7.7 Hz, 2H), 7.46-7.42 (m, 2H), 7.37 (d, J=8.2 Hz, 2H), 7.23-7.18 (m, 2H), 4.25 (t, J=7.1 Hz, 2H), 2.89-2.82 (m, 2H), 2.28 (t, J=7.9 Hz, 2H), 1.86-1.58 (m, 8H), 1.55-1.45 (m, 2H), 1.40-1.24 (m, 5H), 0.83 (d, J=6.5 Hz, 3H)
Example 2.40: 9-(6-(3,5-Dimethylpiperidin-1-yl)hexyl)-9H-carbazole
91.3 mg (0.25 mmol, 83% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and 3,5-dimethylpiperidine (0.05 ml, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.07 (d, J=7.7 Hz, 2H), 7.45-7.41 (m, 2H), 7.35 (d, J=8.2 Hz, 2H), 7.20 (td, J=7.4 Hz, J=0.9 Hz, 2H), 4.23 (t, J=7.1 Hz, 2H), 2.80 (brdt, J=10.5 Hz, J=1.7 Hz, 2H), 2.25-2.21 (m, 2H), 1.88-1.65 (m, 5H), 1.50-1.22 (m, 9H), 0.92 (d, J=6.8 Hz, 1H), 0.81 (d, J=6.5 Hz, 5H)
Example 2.41: 9-(6-(Azepan-1-yl)hexyl)-9H-carbazole
57.5 mg (0.16 mmol, 54% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and hexamethyleneimine (0.04 ml, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.06 (d, J=7.7 Hz, 2H), 7.45-7.41 (m, 2H), 7.36 (d, J=8.2 Hz, 2H), 7.22-7.18 (m, 2H), 4.25 (t, J=6.9 Hz, 2H), 3.03 (brs, 3H), 2.75-2.71 (m, 2H), 1.86-1.63 (m, 12H), 1.35-1.18 (m, 5H)
Example 2.42: 4-(6-(9H-carbazol-9-yl)hexyl)morpholine
97.0 mg (0.29 mmol, 95% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and morpholine (0.03 ml, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.06 (d, J=7.8 Hz, 2H), 7.42 (t, J=7.6 Hz, 2H), 7.35 (d, J=8.1 Hz, 2H), 7.19 (t, J=7.4 Hz, 2H), 4.23 (t, J=7.1 Hz, 2H), 3.66 (t, J=4.5 Hz, 4H), 2.33 (s, 4H), 2.21 (t, J=7.5 Hz, 2H), 1.82 (quint, J=7.2 Hz, 2H), 1.43-1.27 (m, 6H)
Example 2.43: 9-(6-(4-Phenylpiperidin-1-yl)hexyl)-9H-carbazole
92.9 mg (0.21 mmol, 69% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and 4-phenylpiperidine (59 mg, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.06-8.04 (m, 2H), 7.44-7.39 (m, 2H), 7.34 (d, J=8.2 Hz, 2H), 7.27-7.16 (m, 7H), 4.22 (t, J=7.0 Hz, 2H), 3.15 (brd, J=11.6 Hz, 2H), 2.54-2.44 (m, 3H), 2.25 (brt, J=11.3 Hz, 2H), 2.16-2.05 (m, 2H), 1.84-1.79 (m, 4H), 1.61-1.53 (m, 2H), 1.35-1.18 (m, 4H)
Example 2.44: 9-(6-(4-Benzylpiperidin-1-yl)hexyl)-9H-carbazole
83.0 mg (0.18 mmol, 59% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and 4-benzylpiperidine (0.06 mg, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.05 (d, J=7.7 Hz, 2H), 7.41 (td, J=7.6 Hz, J=1.1 Hz, 2H), 7.33 (d, J=8.2 Hz, 2H), 7.25-7.13 (m, 5H), 7.10-7.08 (m, 2H), 4.20 (t, J=7.1 Hz, 2H), 2.84 (brd, J=11.7 Hz, 2H), 2.48 (d, J=7.0 Hz, 2H), 2.20 (t, J=7.9 Hz, 2H), 1.83-1.76 (m, 4H), 1.57 (brd, J=12.8 Hz, 2H), 1.50-1.19 (m, 9H)
Example 2.45: 1-(4-(6-(9H-carbazol-9-yl)hexyl)piperazin-1-yl)ethanone
103.6 mg (0.27 mmol, 91% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and acetylpiperazine (47 mg, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.07 (d, J=7.6 Hz, 2H), 7.44-7.40 (m, 2H), 7.35 (d, J=8.2 Hz, 2H), 7.22-7.18 (m, 2H), 4.24 (t, J=7.1 Hz, 2H), 3.55 (t, J=5.1 Hz, 2H), 3.34 (t, J=5.1 Hz, 2H), 2.27 (t, J=4.6 Hz, 4H), 2.20 (t, J=7.4 Hz, 2H), 2.02 (s, 3H), 1.83 (quint, J=7.3 Hz, 2H), 1.41-1.21 (m, 6H)
Example 2.46: 9-(6-(4-Methylpiperazin-1-yl)hexyl)-9H-carbazole
62.0 mg (0.18 mmol, 59% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and methylpiperazine (0.04 ml, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.08 (d, J=7.7 Hz, 2H), 7.44 (t, J=7.6 Hz, 2H), 7.37 (d, J=8.1 Hz, 2H), 7.23-7.19 (m, 2H), 4.26 (t, J=7.1 Hz, 2H), 2.43 (brs, 10H), 2.28-2.24 (m, 3H), 1.85 (quint, J=7.3 Hz, 2H), 1.47-1.25 (m, 6H)
Example 2.47: 9-(6-(4-Benzylpiperazin-1-yl)hexyl)-9H-carbazole
111.2 mg (0.24 mmol, 79% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and benzylpiperazine (0.06 ml, 0.36 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.07-8.05 (m, 2H), 7.44-7.40 (m, 2H), 7.34 (d, J=8.2 Hz, 2H), 7.30-7.19 (m, 7H), 4.23 (t, J=7.2 Hz, 2H), 3.47 (s, 2H), 2.42 (brs, 8H), 2.23 (t, J=7.6 Hz, 2H), 1.82 (quint, J=7.3 Hz, 2H), 1.44-1.23 (m, 6H)
Example 2.48: 2-(4-(6-(9H-carbazol-9-yl)hexyl)piperazin-1-yl)phenol
111.2 mg (0.26 mmol, 86% yield) of the title compound was prepared using the compound of Example 1.4 (100 mg, 0.30 mmol) and 1-(2-hydroxyphenyl)piperazine (81 mg, 0.45 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.06 (d, J=7.7 Hz, 2H), 7.43-7.39 (m, 2H), 7.34 (d, J=8.2 Hz, 2H), 7.20-7.16 (m, 2H), 7.10 (dd, J=5.9 Hz, J=1.5 Hz, 1H), 7.02 (td, J=7.7 Hz, J=1.3 Hz, 1H), 6.92 (dd, J=6.0 Hz, J=1.4 Hz, 1H), 6.81 (td, J=7.6 Hz, J=1.5 Hz, 1H), 4.21 (t, J=7.1 Hz, 2H), 2.83 (t, J=4.7 Hz, 4H), 2.48 (brs, 3H), 2.26 (t, J=7.6 Hz, 2H), 1.82 (quint, J=7.3 Hz, 2H), 1.44-1.25 (m, 7H)
Example 2.49: 9-(6-(4-(2-Methoxyphenyl)piperazin-1-yl)hexyl)-9H-carbazole
650 mg (1.47 mmol, 49% yield) of the title compound was prepared using 1-(2-methoxyphenyl)piperazine (699 mg, 3.64 mmol), the compound of Example 1.4 (1 g, 3.03 mmol), and K2CO3 (418 mg, 3.03 mmol) in accordance with the procedure of Example 235
1H NMR (400 MHz, CDCl3) δ 8.23 (d, J=7.2 Hz, 2H), 7.58 (t, J=7.6 Hz, 2H), 7.50 (d, J=8.1 Hz, 2H), 7.36 (t, J=7.4 Hz, 2H), 7.13-7.04 (m, 3H), 6.95 (d, J=7.7 Hz, 1H), 4.35 (t, J=7.0 Hz, 2H), 3.94 (s, 3H), 3.21 (brs, 4H), 2.73 (brs, 4H), 2.46 (t, J=7.5 Hz, 2H), 1.99-1.94 (m, 2H), 1.60-1.47 (m, 4H)
Example 2.50: 9-(5-(4-Phenylpiperidin-1-yl)pentyl)-9H-carbazole
226.4 mg (0.52 mmol, 83% yield) of the title compound was prepared using the compound of Example 1.5 (200 mg, 0.63 mmol) and 4-phenylpiperidine (153 mg, 0.95 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.04 (d, J=7.7 Hz, 2H), 7.42-7.38 (m, 2H), 7.32 (d, J=8.2 Hz, 2H), 7.24-7.12 (m, 7H), 4.18 (t, J=6.8 Hz, 2H), 3.10 (brd, J=11.7 Hz, 2H), 2.52-2.41 (m, 3H), 2.29 (t, J=11.4 Hz, 2H), 2.16-2.05 (m, 2H), 1.82-1.73 (m, 4H), 1.63-1.55 (m, 2H), 1.22 (quint, J=7.7 Hz, 2H)
Example 2.51: 9-(5-(4-Benzylpiperazin-1-yl)pentyl)-9H-carbazole
248.0 mg (0.60 mmol, 95% yield) of the title compound was prepared using the compound of Example 1.5 (200 mg, 0.63 mmol) and benzylpiperazine (0.13 ml, 0.76 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.04 (d, J=7.7 Hz, 2H), 7.41-7.37 (m, 2H), 7.30 (d, J=8.2 Hz, 2H), 7.26-7.15 (m, 7H), 4.17 (t, J=7.1 Hz, 2H), 3.44 (s, 2H), 2.39 (brs, 8H), 2.19 (t, J=7.7 Hz, 2H), 1.79 (quint, J=7.4 Hz, 2H), 1.43 (quint, J=7.6 Hz, 2H), 1.28 (quint, J=7.6 Hz, 2H)
Example 2.52: 2-(4-(5-(9H-carbazol-9-yl)pentyl)piperazin-1-yl)phenol
172.3 mg (0.42 mmol, 66% yield) of the title compound was prepared using the compound of Example 1.5 (200 mg, 0.63 mmol) and 1-(2-hydroxyphenyl)piperazine (169 mg, 0.95 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.04 (d, J=7.7 Hz, 2H), 7.42-7.38 (m, 2H), 7.31 (d, J=8.2 Hz, 2H), 7.19-7.15 (m, 2H), 7.09-7.06 (m, 1H), 7.03-6.99 (m, 1H), 6.92 (dd, J=6.0 Hz, J=1.5 Hz, 1H), 6.80 (td, J=7.6 Hz, J=1.5 Hz, 1H), 4.16 (t, J=7.1 Hz, 2H), 2.79 (t, J=4.7 Hz, 4H), 2.41 (brs, 4H), 2.20 (t, J=7.6 Hz, 2H), 1.79 (quint, J=7.4 Hz, 2H), 1.41 (quint, J=7.5 Hz, 2H), 1.32-1.24 (m, 2H)
Example 2.53: 9-(5-(4-(2-Methoxyphenyl)piperazin-1-yl)pentyl)-9H-carbazole
247.7 mg (0.58 mmol, 92% yield) of the title compound was prepared using the compound of Example 1.5 (200 mg, 0.63 mmol) and 1-(2-methoxyphenyl)piperazine (0.13 ml, 0.76 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.05 (d, J=7.7 Hz, 2H), 7.43-7.39 (m, 2H), 7.32 (d, J=8.2 Hz, 2H), 7.20-7.16 (m, 2H), 6.95-6.84 (m, 3H), 6.77 (d, J=7.6 Hz, 1H), 4.18 (t, J=7.1 Hz, 2H), 3.76 (s, 3H), 3.04 (brs, 4H), 2.55 (brs, 4H), 2.27 (t, J=7.7 Hz, 2H), 1.81 (quint, J=7.4 Hz, 2H), 1.48 (quint, J=7.6 Hz, 2H), 1.31 (quint, J=7.6 Hz, 2H)
Example 2.54: 9-(4-(4-Phenylpiperidin-1-yl)butyl)-9H-carbazole
213.5 mg (0.56 mmol, 84% yield) of the title compound was prepared using the compound of Example 1.6 (200 mg, 0.66 mmol) and 4-phenylpiperidine (160 mg, 0.99 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.02 (d, J=7.7 Hz, 2H), 7.40-7.36 (m, 2H), 7.30 (d, J=8.2 Hz, 2H), 7.23-7.09 (m, 7H), 4.14 (t, J=7.2 Hz, 2H), 2.85 (brd, J=11.2 Hz, 2H), 2.36-2.29 (m, 1H), 2.21 (t, J=7.5 Hz, 2H), 1.87-1.67 (m, 8H), 1.49 (quint, J=7.6 Hz, 2H)
Example 2.55: 2-(4-(4-(9H-carbazol-9-yl)butyl)piperazin-1-yl)phenol
104.5 mg (0.26 mmol, 40% yield) of the title compound was prepared using the compound of Example 1.6 (200 mg, 0.66 mmol) and 1-(2-hydroxyphenyl)piperazine (177 mg, 0.99 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.06 (d, J=7.7 Hz, 2H), 7.45-7.41 (m, 2H), 7.37 (d, J=8.1 Hz, 2H), 7.22-7.18 (m, 2H), 7.09 (dd, J=5.9 Hz, J=1.5 Hz, 1H), 7.05-7.01 (m, 1H), 6.92 (dd, J=6.0 Hz, J=1.4 Hz, 1H), 6.81 (td, J=7.6 Hz, J=1.5 Hz, 1H) 4.25 (t, J=7.1 Hz, 2H), 2.80 (t, J=4.7 Hz, 4H), 2.45 (brs, 4H), 2.31 (t, J=7.4 Hz, 2H), 1.86 (quint, J=7.4 Hz, 2H), 1.52 (quint, J=7.5 Hz, 2H)
Example 2.56: 9-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-9H-carbazole
256.4 mg (0.62 mmol, 94% yield) of the title compound was prepared using the compound of Example 1.6 (200 mg, 0.66 mmol) and 1-(2-methoxyphenyl)piperazine (0.14 ml, 0.79 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.04 (d, J=7.7 Hz, 2H), 7.42-7.38 (m, 2H), 7.33 (d, J=8.1 Hz, 2H), 7.19-7.15 (m, 2H), 6.95-6.88 (m, 1H), 6.85 (d, J=4.0 Hz, 2H), 6.75 (d, J=7.8 Hz, 1H), 4.18 (t, J=7.2 Hz, 2H), 3.74 (s, 3H), 3.00 (brs, 4H), 2.50 (brs, 4H), 2.31 (t, J=7.4 Hz, 2H), 1.81 (quint, J=7.4 Hz, 2H), 1.50 (quint, J=7.5 Hz, 2H)
Example 2.57: 9-(3-(4-Phenylpiperidin-1-yl)propyl)-9H-carbazole
132.9 mg (0.36 mmol, 52% yield) of the title compound was prepared using the compound of Example 1.7 (200 mg, 0.69 mmol) and 4-benzylpiperidine (168 mg, 1.04 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.06 (dt, J=7.7 Hz, J=0.8 Hz, 2H), 7.46-7.40 (m, 4H), 7.29-7.26 (m, 2H), 7.23-7.15 (m, 5H), 4.32 (t, J=6.7 Hz, 2H), 2.90 (brd, J=11.5 Hz, 2H), 2.46-2.38 (m, 1H), 2.27 (t, J=6.8 Hz, 2H), 1.99 (quint, J=6.8 Hz, 2H), 1.93-1.85 (m, 2H), 1.83-1.71 (m, 4H)
Example 2.58: 9-(3-(4-Benzylpiperazin-1-yl)propyl)-9H-carbazole
204.6 mg (0.53 mmol, 77% yield) of the title compound was prepared using the compound of Example 1.7 (200 mg, 0.69 mmol) and benzylpiperazine (0.14 ml, 0.83 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.04-8.02 (m, 2H), 7.41-7.36 (m, 4H), 7.30-7.24 (m, 4H), 7.23-7.14 (m, 3H), 4.26 (t, J=6.7 Hz, 2H), 3.46 (s, 2H), 2.39 (brd, J=41.2 Hz, 8H), 2.21 (t, J=6.8 Hz, 2H), 1.92 (quint, J=6.7 Hz, 2H)
Example 2.59: 2-(4-(3-(9H-carbazol-9-yl)propyl)piperazin-1-yl)phenol
131.6 mg (0.34 mmol, 60% yield) of the title compound was prepared using the compound of Example 1.7 (176 mg, 0.61 mmol) and 1-(2-hydroxyphenyl)piperazine (153 mg, 0.86 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.07 (d, J=7.7 Hz, 2H), 7.46-7.41 (m, 4H), 7.24-7.15 (m, 3H), 7.08-7.03 (m, 1H), 6.94 (dd, J=6.0 Hz, J=1.4 Hz, 1H), 6.85 (td, J=7.6 Hz, J=1.5 Hz, 1H), 4.36 (t, J=6.6 Hz, 2H), 2.85 (t, J=4.7 Hz, 4H), 2.47 (brs, 4H), 2.30 (t, J=6.7 Hz, 2H), 2.01 (quint, J=6.6 Hz, 2H)
Example 2.60: 9-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propyl)-9H-carbazole
145.8 mg (0.36 mmol, 60% yield) of the title compound was prepared using the compound of Example 1.7 (176 mg, 0.61 mmol) and 1-(2-methoxyphenyl)piperazine (0.13 ml, 0.73 mmol) in accordance with the procedure of Example 2.35.
1H NMR (400 MHz, CDCl3) δ 8.04 (d, J=7.8 Hz, 2H), 7.43-7.37 (m, 4H), 7.19-7.15 (m, 2H), 6.96-6.86 (m, 3H), 6.78-6.76 (m, 1H), 4.29 (t, J=6.6 Hz, 2H), 3.75 (s, 3H), 3.06 (brs, 4H), 2.50 (brs, 4H), 2.26 (t, J=6.7 Hz, 2H), 1.94 (quint, J=6.6 Hz, 2H)
Formulation Examples
The inventive carbazole derivatives can be formulated into various dosage forms according to the intended purpose. Exemplary formulations containing the carbazole derivatives or pharmaceutically acceptable salts thereof as an active ingredient are provided hereinbelow. However, these formulation examples are merely illustrative and the scope of the present invention is not limited thereto.
Formulation Example 1: Tablets (Direct Compression)
5.0 mg of the compound prepared in Example 2.15 was sieved and mixed with 14.1 mg of lactose, 0.8 mg of crospovidone USNF, and 0.1 mg of magnesium stearate. The mixture was compressed into tablets.
Formulation Example 2: Tablets (Wet Granulation)
5.0 mg of the compound prepared in Example 2.15 was sieved and mixed with 16.0 mg of lactose and 4.0 mg of starch. To the mixture was added an appropriate amount of a solution of 0.3 mg of polysorbate 80 in pure water. The resulting mixture was granulated. After drying, the granules were sieved and mixed with 2.7 mg of colloidal silicon dioxide and 2.0 mg of magnesium stearate. The mixture was compressed into tablets.
Formulation Example 3: Powders and Capsules
5.0 mg of the compound prepared in Example 2.15 was sieved and mixed with 14.8 mg of lactose, 10.0 mg of polyvinylpyrrolidone, and 0.2 mg of magnesium stearate. The mixture was filled in hard No. 5 gelatin capsules using a proper device.
Formulation Example 4: Injectable Preparations
100 mg of the compound prepared in Example 2.15, 180 mg of mannitol, 26 mg of Na2HPO4.12H2O, and 2,974 mg of distilled water were mixed to produce injectable preparations.
Experimental Example 1: Measurement of Binding Affinity for the 5-HT7 Serotonin Receptor
In this example, the human gene recombinant 5-HT7 receptor expressed in CHO cells was used. 1 nM [3H]LSD, 5-HT7 receptor membrane (15 μg/well), a test drug, 10 mM MgCl2, 50 mM Tris-HCl buffer (pH 7.4) containing 0.1 mM EDTA, etc. were added to a vessel until the final volume reached 0.25 ml. The test drug was used at various concentrations. The mixture was cultured at 25° C. for 90 min. The culture was rapidly filtered through a Whatman GF/C glass fiber filter, which had been previously wetted with 0.3% polyethyleneimine using a Brandel harvester, to quench the reaction. The reaction mixture was washed with cold 50 mM Tris-HCl buffer. The filter was covered with MeltiLex, sealed in a sample bag, and dried in an oven. Counting was performed using MicroBeta (Wallac) and nonspecific binding was measured in the presence of 0.5 mianserin. The K value of the test drug was obtained from nonlinear regression analysis (GraphPad Prism Program, San Diego, USA) of isotherms obtained by repeatedly performing the experiment on the drug at 10-11 stage concentrations in two test tubes (each twice).
The % inhibition values of the inventive compounds having different Y structures at a concentration of 10 μM against the 5-HT7 serotonin receptor were measured. Further, the binding affinity (Ki) values of the inventive compounds having different Y structures at a concentration of 10 μM for the 5-HT7 serotonin receptor were measured. The results are shown in Tables 1 to 3.











TABLE 1








Y
5-HT7
5-HT1E
5-HT2C














Example No.
(structure)
% inhibition
Ki (nM)
% inhibition 
Ki (nM)
% inhibition
Ki (nM)





Example 2.1 Example 2.17 Example 2.35




82.8 50.0 70.7
680 1281  511
51.3 73.9 55.7
— — —
87.4 — 59.4
207 — —


 


Example 2.2 Example 2.18 Example 2.36




92.0 83.1 64.0
604 513 1980 
10.2 −22.5  −13.2 
— — —
54.6 32.6 —
1315  — —


 


Example 2.3 Example 2.19 Example 2.37




74.0 57.4 66.9
1051  2157  1546 
13.9 16.3 21.1
— — —
76.7 45.0 —
764 — —


 


Example 2.7 Example 2.23 Example 2.41




86.0 77.0 71.3
616 949 952
 1.8 −11.7   2.7
— — —
77.2 55.0 —
411 1088  —


 


Example 2.4 Example 2.20 Example 2.38




94.2 80.2 82.9
364 592 597
−11.6  −19.3  −9.4
— — —
78.5 44.4 —
878 — —


 


Example 2.5 Example 2.21 Example 2.39




84.6 69.4 75.6
550 883 909
−15.3  −6.0  1.5
— — —
86.6 50.0 —
486 — —


 


Example 2.6 Example 2.22 Example 2.40




77.2 67.6 57.7
833 1398  1598 
−21.9  −10.5  −7.3
— — —
80.6 52.1 —
454 852 —









Referring to the results in Table 1, the compounds wherein Y is NR1R2 (R1 and R2 are alkyl groups that are not bonded to each other and cannot form a ring) showed good inhibitory effects on both 5-HT7 and 5-HT2C, and particularly, they showed very good inhibitory effects on 5-HT1E compared to the other carbazole compounds.
Meanwhile, the compounds wherein Y is NR1R2 and (R1 and R2 are not bonded to each other and cannot form a ring and either R1 or R2 is a benzyl group) and the compounds wherein Y is NR1R2 (R1 and R2 are bonded to each other to form a ring) showed no inhibitory effects on 5-HT1E but showed good inhibitory effects on 5-HT7 and 5-HT2C. Particularly, the compounds in which the alkyl chain between X and Y consists of 5 carbon atoms had significantly high % inhibition values against 5-HT2C.











TABLE 2








Y
5-HT7
5-HT2C
5-HT6














Example No.
(structure)
% inhibition
Ki (nM)
% inhibition
Ki (nM)
% inhibition
Ki (nM)





Example 2.9 Example 2.25 Example 2.43 Example 2.50 Example 2.54 Example 2.57




99.8 96.0 89.9 94.1 94.4 91.1
157 153 212 178 205 353
55.3 53.2 —   — —
758 905 —   — —
92.2 67.0 94.9 96.1 55.5 32.9
373 1496  169 123 1429  —


 


Example 2.10 Example 2.26 Example 2.44




102.9  97.4 86.8
252 312 232
70.4 43.1 —
683 — —
91.9 93.4 97.8
354 302 142









Referring to the results in Table 2, the compounds wherein Y is a substituted piperidinyl group were found to have very high % inhibition values of 89.9 to 103.0 against 5-HT7, together with good inhibitory effects on 5-HT2C and 5-HT6. Meanwhile, the compounds had very low % inhibition values of −12.4 to 13.5 against 5-HT1E. The % inhibition values of the compounds against 5-HT6 were greatly affected by the number (n) of carbon atoms of the alkyl chain between X and Y. Specifically, the compounds in which the alkyl chain consists of 5 carbon atoms had the highest % inhibition values. The % inhibition value decreased significantly with decreasing length of the alkyl chain. The compounds wherein X is CO showed higher % inhibition values against 5-HT7, whereas the compounds wherein X is CH2 showed higher % inhibition values against 5-HT6.












TABLE 3









5-HT7
5-HT1A
5-HT2C
5-HT6













Example No.
Y (structure)
% inhibition
Ki (nM)
% inhibition
% inhibition
% inhibition





Example 2.12 Example 2.28 Example 2.46




50.0 40.4 49.4
1910  — —
 5.5  15.9  19.3
82.5 — —
77.6 78.4 82.2


 


Example 2.11 Example 2.27 Example 2.45




72.1 64.6 63.1
2336  1072  1485 
 51.8  25.4  6.2
51.3  6.6 —
24.5 13.8 35.0


 


Example 2.13 Example 2.29 Example 2.32 Exmaple 2.47 Example 2.51 Example 2.58




94.8 92.0 90.8 86.0 86.8 88.7
127 282 404 602 233 404
76.8 66.5 69.4 62.0 74.9 64.9
72.3 38.0 — — — —
57.9 57.4 14.7 77.5 65.1 15.1


 


Example 2.14




94.1
 73
80.5
63.7
81.3


 


Example 2.15 Example 2.30 Example 2.33 Example 2.48 Example 2.52 Example 2.55 Example 2.59




100.3  98.7 97.0 90.5 94.4 95.8 94.7
 38  86  50  89  31  55  96
94.2 102.2  100.9  105.2  102.6  103.2  104.7 
73.5 — — — — — —
85.3 62.6 16.1 96.9 95.5 77.8 21.7


 


Example 2.16 Example 2.31 Example 2.34 Example 2.49 Example 2.53 Example 2.56 Example 2.60




102.0  99.6 97.7 85.7 91.5 92.5 90.7
 74  30  33 145  65  64 155
108.0  103.2  103.6  104.7  101.1  104.5  102.7 
55.8 62.6 74.2 — — — —
30.7 44.4 51.5 85.1 75.5 56.3 12.2









Referring to the results in Table 3, the compounds wherein Y a piperazinyl groups whose nitrogen atom is substituted with alkyl (R5) showed good inhibitory effects on 5-HT2C and 5-HT6 together with 5-HT7. On the other hand, the compounds wherein R5 is an aryl group, a heteroaryl group or benzyl showed good inhibitory effects on 5-HT1A as well as 5-HT2C and 5-HT6, together with 5-HT7. Particularly, the compounds wherein R5 is an aryl group showed excellent inhibitory effects on 5-HT1A. On the other hand, the compounds in which the alkyl chain consists of 5 carbon atoms had the highest % inhibition values against 5-HT6, as in the results in Table 2. The % inhibition value decreased significantly with decreasing length of the alkyl chain. The compounds wherein X is CO showed higher % inhibition values against 5-HT7, whereas the compounds wherein X is CH2 showed higher % inhibition values against 5-HT6.
Referring to the results in Tables 1-3, when Y has a structure within the range defined above and X is CH2 irrespective of the structure of Y, the compounds wherein n is 5 showed lower % inhibition values against the 5-HT7 receptor compared to the compounds wherein n is from 2 to 4. The compounds wherein n is 5 have a carbazole-(CH2)5—Y structure in which X (CH2) is connected to the alkyl chain ((CH2)5). This structure is estimated to lower the % inhibition values of the compounds wherein n is 5 against the 5-HT7 receptor.
In order to investigate the inhibitory effect of the length of the alkyl chain between the carbazole moiety and the tertiary amine (Y) on the 5-HT7 receptor when n is greater than 5, the compounds wherein n is 6 and the compounds wherein n is 7 were prepared (Comparative Examples 1-6).




The compound of Comparative Example 1 wherein Y is 4-phenylpiperidyl, X is CO, and n is 6 and the compound of Comparative Example 2 wherein Y is 4-phenylpiperidyl, X is CO, and n is 7 were measured to have % inhibition values of 47.5 and 32.8 against the 5-HT7 receptor, respectively, which were lower than those of the compounds of Examples 2.9 and 2.25 shown in Table 2. The compound of Comparative Example 3 wherein Y is 4-phenylpiperidyl, X is CH2, and n is 6 was measured to have a % inhibition value of 42.7 against the 5-HT7 receptor, which was lower than that of the compound of Example 2.43 shown in Table 2.
The compound of Comparative Example 4 wherein Y is 2-methoxyphenylpiperazinyl, X is CO, n is 6, the compound of Comparative Example 5 wherein Y is 2-methoxyphenylpiperazinyl, X is CH2, and n is 6, and the compound of Comparative Example 6 wherein Y is 2-methoxyphenylpiperazinyl, X is CH2, and n is 7 were measured to have % inhibition values of 44.5, 42.7, and 19.7 against the 5-HT7 receptor, respectively, which were lower in efficacy than those of the inventive compounds wherein Y is 2-methoxyphenylpiperazinyl shown in Table 3.
From these results, it can be seen that the compounds wherein n is from 2 to 5 can effectively act on the 5-HT7 receptor. Particularly, the compounds wherein n is 7 or greater had considerably low % inhibition values, making it substantially difficult to apply the compounds as antagonists against the 5-HT7 receptor, and therefore, they are not expected to be useful for the treatment or prevention of central nervous system diseases, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, circadian rhythm dysregulation, sleep disturbance, and smooth muscle-related diseases.
Experimental Example 2: Antagonism Against Migraine
It is known that inflammatory proteins leaked from meningeal vessels by 5-HT are implicated in causing migraine. The amount of the proteins leaked in the presence of the compound of Example 2.10 was measured and the preventive effect of the compound on migraine was assessed by a partial modification of the method described in the literature [Rachel A. Spokes, Vicki C. Middlefell, European Journal of Pharmacology (1995) 281, 75-79]. SB-269970, which is known as a 5-HT7 receptor antagonizing compound (J. Med. Chem. (2000) 43, 342-345), was used as a comparative compound. A negative control free of 5-HT7 was prepared. The fluorescence intensity of the negative control was defined as a reference value. As a positive control, physiological saline was added instead of the compound of Example 2-10.
Rats (350-450 g) were administered urethane (1.5 g/kg) intraperitoneally. 50 mg/kg of a fluorescent protein (FITC-BSA) was administered intravenously through a cannula introduced into the saphenous vein, and 1 μM 5-HT7 was administered intravenously. SB-269970 and the compound of Example 2.10 were administered intraperitoneally. The cerebral lobes were separated and the meninges were drawn from each rat. The meninges were allowed to stand at 37° C. for 16 h in the presence of physiological saline at pH 11, followed by centrifugation. The supernatant was plated on plates. The fluorescence intensity was measured using a fluorescence leader (excitation wavelength 485 nm, absorption wavelength 530 nm) and the meninges were weighed. The fluorescence intensity per mg of the meningeal proteins was calculated.
The 5-HT7 receptor antagonizing compound SB-269970 reduced the amount of the proteins leaked by 10 mg/kg. Even when SB-269970 was administered at an increased dose of 30 mg/kg, the amount of the proteins leaked was not lowered down to the reference value. In contrast, when the compound of Example 2.10 was administered at a dose of 3 mg/kg, the amount of the proteins leaked was effectively suppressed to a level close to the reference value. The results are shown in FIG. 1.
When each of the compounds of Examples 2.4, 2.9, 2.14, 2.15, 2.31, and 2.55 was administered in an amount of 5 mg/kg to 20 mg/kg, the protein leakage was suppressed to a level close to the reference value.
These results lead to the conclusion that the inventive compounds can effectively inhibit migraine.

## Claims

1. A carbazole derivative represented by Formula 1:



wherein X is C(O),
Y is piperazinyl groups in which the nitrogen atom is substituted with R5,
n is an integer from 2 to 5,
and
R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, benzoisoxazol-3-yl or
a pharmaceutically acceptable salt thereof.

2. The carbazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein Y is selected from 4-methylpiperazinyl, 4-acetylpiperazinyl, 4-(2-methoxyphenyl)piperazinyl, 4-(2-hydroxyphenyl)piperazinyl, 4-benzylpiperazinyl, and 4-(benzoisoxazol-3-yl)piperazinyl.

3. The carbazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein the carbazole derivative represented by Formula 1 is selected from:
1-(9H)-carbazol-9-yl)-6-(4-methylpiperazin-1-yl)hexan-1-one;
6-(4-benzylpiperazin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one;
6-(4-benzo[d]isoxazol-3-yl)piperazin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one;
1-(9H-carbazol-9-yl)-6-(4-(2-hydroxyphenyl)piperazin-1-yl)hexan-1-one;
1-(9H-carbazol-9-yl)-6-(4-(2-methoxyphenyl)piperazin-1-yl)hexan-1-one;
5-(4-acetylpiperazin-1-yl)-1-(9H-carbazol-9-yl)pentan-1-one;
1-(9H)-carbazol-9-yl)-5-(4-methylpiperazin-1-yl)pentan-1-one;
5-(4-benzylpiperazinyl)-1-(9H-carbazol-9-yl)pentan-1-one;
1-(9H-carbazol-9-yl)-5-(4-(2-hydroxyphenyl)piperazin-1-yl)pentan-1-one;
1-(9H-carbazol-9-yl)-5-(4-(2-methoxyphenyl)piperazin-1-yl)pentan-1-one;
4-(4-benzylpiperazin-1-yl)-1-(9H-carbazol-9-yl)butan-1-one;
1-(9H-carbazol-9-yl)-4-(4-(2-hydroxyphenyl)piperazin-1-yl)butan-1-one; and
1-(9H-carbazol-9-yl)-4-(4-(2-methoxyphenyl)piperazin-1-yl)butan-1-one.

4. A pharmaceutical composition for preventing and treating a central nervous system disease, comprising a carbazole derivative represented by Formula 1:



wherein X is or C(O),
Y is piperazinyl groups in which the nitrogen atom is substituted with R5,
n is an integer from 2 to 5,
and
R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, benzoisoxazol-3-yl or a pharmaceutically acceptable salt thereof as an active ingredient.

5. The pharmaceutical composition according to claim 4, wherein the carbazole derivative represented by Formula 1 is selected from compounds represented by Formula 4:



wherein X is C(O),
n is an integer from 2 to 5, and
R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl.